Scholarlink

Background <p>Radiotherapy is an established treatment modality for malignant non-Hodgkin lymphoma. However, the complexity of the treatment situations demands precise treatment indication and execution. The following review presents modern radiooncological treatment strategies.</p> Materials and methods <p>A&#xa0;selective literature search addressing radiotherapy of malignant non-Hodgkin lymphoma was conducted, focusing on diffuse large B‑cell lymphoma, marginal zone lymphoma, and follicular lymphoma. Relevant studies as well as the German national S3 guidelines were identified and discussed.</p> Results <p>Indolent lymphoma in early stages can be treated with radiotherapy in curative intent. In carefully selected cases, dose de-escalation may be possible, although it is not recommended by the German S3 guideline. In the case of aggressive non-Hodgkin lymphoma, consolidation radiotherapy is conducted after systemic therapy, addressing regions with an increased risk of recurrence. Particularly patients with positron-emission tomography (PET)-positive residuals should be irradiated. Innovations like the application of radiotherapy before or after chimeric antigen receptor T‑cell therapy and the emerging implementation of online adaptive radiotherapy will enrich the therapeutic landscape in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Strahlentherapie von Non-Hodgkin-Lymphomen – Diskussion moderner Behandlungskonzepte und Innovationen

  • 期刊论文

  • 发表日期：

    2026年2月18日

查看全文
  • Michael Oertel,
  • Hans Theodor Eich

摘要

Background

Radiotherapy is an established treatment modality for malignant non-Hodgkin lymphoma. However, the complexity of the treatment situations demands precise treatment indication and execution. The following review presents modern radiooncological treatment strategies.

Materials and methods

A selective literature search addressing radiotherapy of malignant non-Hodgkin lymphoma was conducted, focusing on diffuse large B‑cell lymphoma, marginal zone lymphoma, and follicular lymphoma. Relevant studies as well as the German national S3 guidelines were identified and discussed.

Results

Indolent lymphoma in early stages can be treated with radiotherapy in curative intent. In carefully selected cases, dose de-escalation may be possible, although it is not recommended by the German S3 guideline. In the case of aggressive non-Hodgkin lymphoma, consolidation radiotherapy is conducted after systemic therapy, addressing regions with an increased risk of recurrence. Particularly patients with positron-emission tomography (PET)-positive residuals should be irradiated. Innovations like the application of radiotherapy before or after chimeric antigen receptor T‑cell therapy and the emerging implementation of online adaptive radiotherapy will enrich the therapeutic landscape in the future.